FDA approves obecabtagene autoleucel for acute …
On November 8, 2024, the FDA approved obecabtagene autoleucel (Aucatzyl, Autolus Inc.) for relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
FDA Approves New CAR T-Cell Therapy for ALL - aabb.org
The U.S. Food and Drug Administration (FDA) approved obecabtagene autoleucel (Aucatzyl), a CD19-directed CAR T-cell immunotherapy developed by Autolus Inc., for adults with relapsed …
FDA Approval of Obecabtagene Autoleucel for B-Cell Acute …
On November 8, 2024, the US Food and Drug Administration (FDA) approved obecabtagene autoleucel (AUCATZYL, Autolus Inc) for the treatment of adults with relapsed or refractory B …
FDA Approves Obecabtagene Autoleucel (Aucatzyl) for …
On Nov. 8, the U.S. Food and Drug Administration (FDA) approved obecabtagene autoleucel (Aucatzyl) for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia …
New CAR T-cell Therapy FDA-Approved for B-cell ALL
Obe-cel, short for obecabtagene autoleucel (Aucatzyl by Autolus Inc.), is a CAR T-cell therapy that was recently FDA-approved on November 8th, 2024, for adults with relapsed/refractory …
Aucatzyl Approved for Relapsed/Refractory B-Cell Acute …
The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic …
Autolus Therapeutics announces FDA approval of AUCATZYL®
Autolus Therapeutics announces FDA approval of AUCATZYL® London, 8 November 2024 - Autolus Therapeutics plc (Nasdaq: AUTL), an early-commercial stage biopharmaceutical …
FDA Approves Obecabtagene Autoleucel for Adults With …
The FDA has granted regulatory approval to obecabtagene autoleucel (Aucatzyl; Autolus Inc), a CD19-directed genetically modified autologous T cell immunotherapy, to treat adults with …
FDA Approves CAR-T Cell Therapy for Relapsed or Refractory B-Cell ALL
The Food and Drug Administration (FDA) approved the CAR-T cell therapy Aucatzyl (obecabtagene autoleucel) for the treatment of adults with relapsed or refractory B-cell …
FDA Approves Obecabtagene Autoleucel in B-Cell ALL
The FDA has approved obecabtagene autoleucel (obe-cel; Aucatzyl) for patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL), according to a press …